drugset / Trial / NCT06663306
Intrathecal Injection Pemetrexed And Bevacizumab in Patients With Leptomeningeal Metastases in NSCLC
Phase 1
Recruiting
19 enrolled
Shanghai Chest Hospital
Innovent Biologics (Suzhou) Co. Ltd. · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a prospective, single-arm, phase Ia clinical study, which was designed to evaluate the efficacy and safety of Pemetrexed Combined With Bevacizumab Intrathecal Injection in Patients With Leptomeningeal Metastases in NSCLC.
Timeline
- Start
- 2024-12-09
- Primary completion
- 2027-12-30
- Completion
- 2027-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 5 mg | Intrathecal |
| Subject | Bevacizumab | Monoclonal antibody | 10 mg | Intrathecal |
| Subject | Bevacizumab | Monoclonal antibody | 25 mg | Intrathecal |
| Subject | Bevacizumab | Monoclonal antibody | 37.5 mg | Intrathecal |
| Subject | Bevacizumab | Monoclonal antibody | 50 mg | Intrathecal |
| Subject | Pemetrexed | Small molecule | 50 mg | Intrathecal |